Member Info for Bella6532

D-Geeman...perhaps it's about money. If you build biopsies into your safety trial you get to see if dox is in the tumour then combine this with a possible scan then you might see it working and then more confident to move on to 1b. If dox wasn't working and simply remained dormant in the tumour then perhaps you could see no side effects and continue upping the dose for what purpose!!

The are listed on NASDAQ at $21 SP. Further ahead than Avacta in trials etc...yes it's an example of where we could be but not just yet. This deal does appear to be somewhat exclusive for Novartis. Many pharmas do this now...cheaper than a full buy out yet giving pretty much the same rights/exclusivity.

Avacta is about licencimg not selling. 1b is key to getting a deal or deals secured for the rest of the pipeline...1b will unlock the potential.

RAH...'If we assume a Q3 start date for P1b (assuming all goes to plan) then Avacta will be seeing, in the first set of patients, whether AVA6000 is curtailing tumour growth by late 2023/early 2024.'

Now here's the thing...does this mean all the dox pumped into the patients thus far hasn't been seen to have reduced any tumours...dox suddenly behaves differently as soon as it's moved to P1b ...
Mmmm! I think we all find such a senario to be rather strange...

Diggers2...what happened last time might give you an indication...

My mystic powers lead me to believe there may well be an RNS on Thursday re next Qtly Principal Payment of £2.5m.
Any large order being filled now...which is quite likely...is probably being done so in advance of the new shares being issued.
Please don't shoot the messenger...it's my mystic other'alf calling this one....

Guys...you never learn...disrupters always appear when someone wants the SP lowering or holding...best to ignore.

Finally, what's the probability of two separate mice trials working followed by in clinical trials for both failing...pretty much no chance...so sit back and ignore the noise...both work in mice and both will work in humans and the rest is (will be) history.

What do they have that's proven??? We are still only in safety trials!!!

AIM was set up so PIs could invest in early stage companies whuch up until then were only available to IIs. For Avacta to apply for a NASDAQ listing they have to fulfill certain criteria re turnover etc. It would be far simpler to do a RTO into an already listed company or acquire one which meets their acquisition needs...there are plenty available and it could be to grow the Launch side of the business. The upcoming results with a good forward looking statement and some supporting updates/news/timescales could help nudge the SP up. It's all about what is going to make money for the IIs...

Retireby40...how many people do you know with long Covid?
500 unnecessary deaths right now due doctors strike...during covid only 600 or so per day died and had Covid on the death certificate...go figure!!!
Avacta gained huge amounts of info re their affimers in LFTs. Some of their new Launch customers have LFTs in their portfolio (not necessarily for Covid). I suspect Zvacta will use their data/info to try and encourage others to adopt our affimers in their diagnostics equipment including LFTs and again not necessarily for Covid.

Experimental: AVA6000 Phase 1b
Patients in Phase Ib will receive the RP2D dose of AVA6000, once every 3 weeks (Q3W) starting on Cycle 1, Day 1 (C1D1), until disease progression, unacceptable toxicities, withdrawal from treatment for other reasons, reaching maximum lifetime cumulative exposure to doxorubicin (or other anthracyclines), or death, whichever occurs first. One to three tumour types will be selected based on the assessment of Phase 1a data

RMFatGB...you forgot to mention that Launch Diagnostics are now part of the Avacta group.

We might see a lttle Revenue in the results...if so, it will help give an indication as to what sort of contribution we might expect to see this year...better still a company stated forward indication would be even better.

Maybe it's because it's a totally untapped market place and there's possibly already someone interested in it?

'3996 was suggested to be agnostic due to the way a protease inhibitor works.
Ava6000 is not tumour agnostic.'

Yes..the two are completely different and in the way they kill cancer cells.
AVA6000 zaps where as 3996 cuts of the cells ability to get ride of it's own waste which by doing so then kills the cancer cells.

Dox is a nasty drug which in itself can induce drug resistance coupled with horrendous side effects and can only be administered broadly rather than targetted.

The case for AVA6000 is not just about reduced or even no side effects...and it's not even about it's targetting ability to seek out and find cancer cells whereever they may be lurking at what ever size/stage (clearly visable or not)...it's also about getting much, much, much higher dosages directly into the cancer cells as quickly as possible so as to also overcome any possible drug resistance which may take effect.

I will also say again...if it has been seen that Dox is not doing what it says on the tin when released into the tumours then it wouldn't make sense to a) up the dose b) continue the trial.

As was said by AS...they are having to continue down the standard trial route right now because that's what the Regulators want and expect regardless of what 'efficasy' results may have been noted to date. There is a tried and tested test path...SAFETY, MTD, EFFICASY and each stage has to come up to scratch and be proven with sound data and that is how it should be. We, unfortunately, just like potential recipients (patients) and Avacta have to wait it out.....

These patients are terminal...why would approval for more dosage increases be given if there wasn't some indication the dox was acting normally. They would never approve continuing the trial if dox wasn't doing what it said on the tin because terminal patients don't need dox and wouldn't be given it otherwise.
Scans, blood test and biopsies will have given some indication as to what the dox was doing even though this data is outside the 1a trial criteria.

Myles M post on Twitter Aug 2022 below. If Avacta want to cut an upfront payment deal for 3996 then Takeda are obvious target and as a shareholder they could have been given 'insider' status to allow them to see the data from 6000 and 3996 mouse trials.
'Japanese major pharma Takeda ($44bn cap) has recently bought shares in @avacta!
#AVCT's second pre CISION prodrug is 3996, an analogue of the protease inhibitor, bortezomib.
Takeda markets Velcade, a branded version of bortezomib, in the US.'

Is it possible we could do a good upfront payment deal for 3996 before we go to stage two with 6000 and therefore this helps the needed funding...

BV here's an example...
https://www.patheon.com/us/en/our-capabilities/commercial-services.html

BV...'The big questions I have are: who will be the manufacturing, marketing and distribution partners; and which geographic markets will they have exclusive rights to.'
In the US there are Contract Manufacturers who will do all this for you...if Avacta want to kerp AVA6000 for themselves then this would be the obvious route.

Great post Icecool...now here's a thing...AS in the Vox interview did emphasis that ia is all about safety and has to be carried and the trial has to go through all it stages to satisfy the regulators. That's the key isn't it...regulators need to be satisfied and it doesn't matter what other findings there might be at this stage it's all about the regulators.